Miguel A Pavlovsky MD
@Pavlovsky_Mig
Lymphoma and CLL - FUNDALEU Buenos Aires, Argentina .
Mark your calendar for the 6th Meeting / Latin American Group on CLL on April 2026 in beautiful Mendoza!! With regional and international speakers with cheese and wine (Malbec) posters reception ✅
Impressive results for high risk BTK exposed MCL RR patients
ICML25: Outpatient fixed duration Mosun-Pola regimen is highly efficacious in 3L+ R/R MCL in this phase 2 cohort: 71% had 3+ high risk features (prior CAR, ASCT, TP53, Blastoid/pleomorphic, Ki67 30%+ etc). ORR 88%, CR79% CRS all low grade and resolved.
ICML25: Outpatient fixed duration Mosun-Pola regimen is highly efficacious in 3L+ R/R MCL in this phase 2 cohort: 71% had 3+ high risk features (prior CAR, ASCT, TP53, Blastoid/pleomorphic, Ki67 30%+ etc). ORR 88%, CR79% CRS all low grade and resolved.
(A) Two-year PFS in patients 60 years and older on S1826 by arm. (B) Two-year OS in patients 60 years and older on S1826 by arm. BV, brentuximab vedotin; HR, hazard ratio; N, nivolumab; OS, overall survival; PFS, progression-free survival. #lymsm #Hodgkin #lymphoma #geriheme
“Nivo-AVD was better tolerated and more effective than Bv-AVD and is therefore a new standard of care for older patients with advanced-stage cHL fit for anthracycline-based combination therapy” @JCO_ASCO ascopubs.org/doi/10.1200/JC…
Evidence that CLL is a multiclone disease !! Very nice work 👏👏
Beautiful CLL genetics work presented by Dr. Ian Marquez-Lopez (Campo’s lab) at #EHA2025 showing that CLL is characterized, in a fraction of patients, by the expansion of multiple clones with distinct molecular features. These clones seem arise decades earlier in life #CLLsm
EHA 2025 - ECHO trial: nice to be part of an international effort thanks to our patients and wonderful team at FUNDALEU
When patient seems to be lost after median of 6 lines of tx for MM!! Amazing results
#1 CARTITUDE 1 Outstanding longterm efficacy with cilta-cel CAR-T in refractory myeloma median 6 prior lines of therapy. #ASCO25 5 yr survival 50% 5 yr PFS 33% @PlasmaCellPete @NoopurRajeMD @TomBmt133 @YiLinMDPhD @DMadduri @bhemato @BerdejaJesus meetings.asco.org/abstracts-pres…
Impressive prospective results !! Should we do something different for those with MRD+ as consolidation with ASCT?
CONGRESS | #ASCO25 | PRESENTATION Steven Wang @wngsteven @amsterdamumc presents results from a prospective validation of end-of-treatment ctDNA-MRD by PhasED-Seq in patients with DLBCL treated with 1L R-CHOP or DA-EPOCH-R in a national cohort (N = 160). MRD+ status significantly…
Total Metabolic Tumor Volume is a strong independent prognostic factor in Follicular #Lymphoma: results from a sub-study of the FOLL12 trial doi.org/10.1002/ajh.27… @filonlus
Great results: Cilta-cel should be available in LMIC
The most impressive myeloma abstract at #ASCO25 Outstanding longterm efficacy with cilta-cel CAR-T. 5 year survival rate 50% 5 year PFS rate of 33% Astounding given multi-drug relapsed refractory setting. @PlasmaCellPete @NoopurRajeMD @TomBmt133 @YiLinMDPhD @DMadduri…
Congrats for an outstanding event
I am super excited to be in the amazing Buenos Aires 🇦🇷🇦🇷🇦🇷 for the Jornadas GATMO and network with colleague from all Latin America on #MDS and allo-HCT Thanks @GonzaloBentoli1 @MikaQ06
Proud of our FUNDALEU team with @GonzaloBentoli1 hosting our national BMT and cellular therapy meeting with outstanding speakers @NicoGagelmann @CarmeloGurnari
Such a pleasure to connect with and learn from colleagues in Argentina, Uruguay... about challenges in transplantation. Wonderful and fascinating discussions! Building and expanding friendship @GonzaloBentoli1 @CarmeloGurnari @MikaQ06 in times of division🙏❤️#GATMO2025
🔬 ¿Por qué necesitamos ensayos clínicos? Los ensayos clínicos son esenciales para el desarrollo de nuevas intervenciones y ofrecer nuevas opciones terapéuticas. Sin ellos, no podemos determinar si un medicamento es seguro o si una prueba diagnóstica funciona en el ámbito clinico
Clinical research so important for our patients = new tx options + better care ✅
Big things are happening in Buenos Aires this week! 🧬 GATMO 2025 is just around the corner! 📅 May 23–24 | 📍CABA We can’t wait to welcome you! (🥳) Let’s talk science, share ideas & have some fun! ✨ See you there! #GATMO2025 #NextGenHematology #Networking
⏳ ¡Falta muy poco! Te esperamos en las Jornadas del GATMO de @SAHematologia, el 23 y 24 de mayo. Actualización en trasplante y terapias celulares con referentes nacionales e internacionales. 📍 Inscribite en: gatmo.sahonline.com.ar #GATMO #SAH #Hematología #Trasplante